Target intelligence / Profile preview

Proteasome 20S subunit beta 1 (PSMB1)

Target
PSMB1
Molecular classification
Enzyme (specifically, protease subunit of the 20S proteasome complex), Multicatalytic endopeptidase complex component
01

Overview

Proteasome 20S subunit beta 1 (PSMB1) is a non-catalytic structural subunit of the 20S core proteasome, an essential multicatalytic protease complex responsible for the ATP/ubiquitin-dependent degradation of most intracellular proteins in eukaryotic cells. PSMB1, together with other beta subunits, forms part of the proteolytic chamber necessary for regulated protein degradation, playing vital roles in processes including cell cycle control, apoptosis, transcription, immune responses, and degradation of damaged or misfolded proteins. Together, these processes are fundamental to cellular protein homeostasis and regulation. Dysfunction or dysregulation of the proteasome (including PSMB1) is implicated in the pathogenesis of cancer, neurodegeneration, cardiovascular disease, inflammation, and autoimmune disorders. PSMB1, as a notable proteasome subunit, is considered a therapeutic target as part of the proteasome complex, targeted by several approved proteasome inhibitors in oncology and experimental therapeutics.

Other names
Proteasome subunit beta type-1Proteasome subunit beta-1Proteasome subunit beta-6Proteasome component C5Proteasome gamma chainHC5PSC5PMSB1NEDMHALMacropain subunit C5Multicatalytic endopeptidase complex subunit C5Proteasome (prosome, macropain) subunit, beta type, 1testicular secretory protein Li 45
02

Mechanism of action

Inhibition of proteasome-mediated proteolysis prevents degradation of key regulatory proteins, leading to cell cycle arrest, apoptosis, and anti-tumor effects (as with bortezomib and related drugs)

03

Biological functions

Protein degradation (proteolysis)Protein quality controlRegulation of cell cycleRegulation of apoptosisSignal transductionImmune response (antigen processing for MHC class I)Gene transcription regulation (via degradation of transcription factors)
04

Disease associations

Cancer (including various malignancies via impact on protein degradation and regulatory factor turnover)Neurodegenerative disease (e.g., Alzheimer's, Parkinson's, ALS, Huntington's)Cardiovascular disease (e.g., cardiac ischemia, heart failure)InflammationAutoimmune disease (e.g., SLE, Sjögren syndrome, rheumatoid arthritis)Neurodevelopmental disorder with microcephaly, hypotonia, and absent language
05

Safety considerations

Proteasome inhibitor therapy can result in toxicity including peripheral neuropathyProteasome inhibitor therapy can result in immunosuppressionProteasome inhibitor therapy can result in increased risk of infection (due to inhibition of protein turnover and immune protein regulation)
06

Interacting drugs

General proteasome inhibitors: bortezomib

2 more in the full profile.

07

Biomarkers

Circulating proteasomes (including PSMB1) as potential biomarkers in autoimmune diseases and certain cancers

Beyond the preview

Go deeper on Proteasome 20S subunit beta 1 (PSMB1).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Proteasome 20S subunit beta 1 (PSMB1).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call